Economic information and modeling report
Modeling overview
8 evidence topics · 5 sources
Summary: published economic evidence and company market statements
- The report holds no published cost-effectiveness analysis, health technology assessment, or analyst sales forecast for ersodetug in tumor hyperinsulinism. All economic statements come from the manufacturer.
- The manufacturer's U.S. patient estimates use different measures: approximately 3,000 patients per year as the “immediately addressable incidence market” (Form 10-K), approximately 4,000 patients per year on the same measure (Form 10-Q), approximately 4,500 patients as the “total addressable market” (2024 release, which states that including NICTH would more than double the population), and about 2,500 malignant insulinoma and about 1,500 NICTH patients as a point-in-time prevalence as of October 2026 from the Veeva Compass claims database (October 2026 presentation).
- The October 2026 presentation gives a tumor HI market of about 4,000 patients and a total addressable market of $4 to 5 billion, a combined U.S. opportunity of about 6,000 patients, and a global market opportunity of more than $5 billion.
- Company payer research describes the indications as having low budgetary impact that supports ultra-rare disease pricing, and states likely payer acceptance of weight-based pricing. At a 9 mg/kg maintenance dose and an average adult weight of about 80 kg, the company assumes 9 vials per infusion and 117 vials per year per patient with infusion every four weeks.
- The primary payer in the company's claims data was Medicare for 48.6% of patients, commercial insurance for 43.9%, Medicaid for 5.5%, and other payers for 2.0%.
Company estimates of the immediately addressable U.S. tumor hyperinsulinism population per year
Earlier company estimate of the total addressable U.S. tumor hyperinsulinism market including NICTH
Claims-based count of addressable U.S. patients with malignant insulinoma and NICTH
| Field | Corporate presentation, October 2026 |
|---|---|
| Malignant insulinoma | “~2,500 Addressable Malignant Insulinoma Patients in the U.S.” |
| Malignant insulinoma claims definition | “ICD - 10 code C25.4 is for malignant neoplasm of the endocrine pancreas, or cancer of the endocrine pancreas” |
| Repeated hospitalization criterion | “inpatient or emergency department encounters with a hypoglycemia - related diagnosis” |
| NICTH | “~1,500 Addressable NICTH Patients in the U.S.” |
| NICTH claims definition | “Patients with qualifying tumor” |
| Measure | “Point - in - time prevalence as of Oct 2026.” |
| Data source | “Source: Veeva Compass database; covers more than 70% of US patients” |
Company payer research on pricing, utilization management, and reimbursement
Tumor hyperinsulinism payer mix in claims data
| Primary payer | Share of patients |
|---|---|
| Commercial | “43.9%” |
| Medicare | “48.6%” |
| Medicaid | “5.5%” |
| Other | “2.0%” |
| Assignment method | “Primary payer assigned from the most frequently observed claim dates.” |
| Other payers | “Other include VA, DoD, etc.” |
Weight-based dosing and vial use per patient in tumor hyperinsulinism
Company market opportunity estimates for tumor hyperinsulinism and combined indications
Published analyst sales forecasts for ersodetug in tumor hyperinsulinism
No evidence found.
Health technology assessments and published economic evaluations of ersodetug
No evidence found.